NCT03711253

Empiric Treatment for Acute HIV in the ED

Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An acceptance and feasibility study for immediate ART initiation and storage of laboratory specimens for individuals with suspected acute HIV infection who are diagnosed in one of the 7 participating emergency rooms

Detailed description

Individuals with suspected acute HIV infection willing to start immediate ART treatment will be given the ART regimen (bictegravir 50mg + tenofovir alafenamide 25 mg + emtricitabine 200 mg fixed dose combination) on the day of diagnosis. Those patients beginning immediate ART in the ED who are willing to have additional laboratory specimens drawn in the ED and become part of a cohort to receive ART and have ongoing biological specimens obtained and will be followed for 48 weeks.

Conditions

• Acute HIV Infection

Interventions

Type	Name	Description
DRUG	Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg	antiretroviral therapy

Timeline

• Start date: 2019-10-14
• Primary completion: 2023-06-01
• Completion: 2023-06-01
• First posted: 2018-10-18
• Last updated: 2023-04-26

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study